NCT06898684 Medulloblastoma Online Video-based Exercise Pilot Study
| NCT ID | NCT06898684 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aron Onerup |
| Condition | Medulloblastoma, Childhood |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-12-09 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2025-12-09 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma. The exercise sessions will be individualized and offered three times weekly during 12 weeks.
Eligibility Criteria
Inclusion Criteria: Completed therapy for medulloblastoma, including craniospinal radiation therapy, within 36 months before study entry. \- Exclusion Criteria: Inability to walk without support. Progressive disease. \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06898684 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 18 Years, studying Medulloblastoma, Childhood. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898684 currently recruiting?
Yes, NCT06898684 is actively recruiting participants. Contact the research team at aron.onerup@gu.se for enrollment information.
Where is the NCT06898684 trial being conducted?
This trial is being conducted at München, Germany, Gothenburg, Sweden.
Who is sponsoring the NCT06898684 clinical trial?
NCT06898684 is sponsored by Aron Onerup. The trial plans to enroll 15 participants.